Improved nasal absorption of salmon calcitonin by powdery formulation with N-acetyl-L-cysteine as a mucolytic agent

被引:42
作者
Matsuyama, Takahiro [1 ]
Morita, Takahiro [1 ]
Horikiri, Yuji [1 ]
Yamahara, Hiroshi [1 ]
Yoshino, Hiroyuki [1 ]
机构
[1] Tanabe Seiyaku Co Ltd, CMC Res Labs, Dept Pharmaceut Technol, Yodogawa Ku, Osaka 5328505, Japan
关键词
nasal absorption; absorption enhancement; powdery formulation; mucolytic agent; salmon calcitonin;
D O I
10.1016/j.jconrel.2006.08.004
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
To establish a new formulation technology for the nasal delivery of peptide and protein drugs, we examined whether a mucolytic agent, Nacetyl-L-cysteine (NAC), could enhance the nasal absorption of a powder form of salmon calcitonin, a model peptide drug. We used ethylcellulose as an inert water-insoluble excipient. Various test formulations were prepared, and the effects on nasal absorbability were evaluated in rats and dogs. The powder formulation with NAC gave significant nasal absorption of SCT in both animal models, with absolute bioavailabilities of 30.0% in rats and 24.9% in dogs. Also, nasal administration of this formulation gave a quicker absorption rate than subcutaneous administration of SCT. NAC may reduce nasal fluid viscocity and improve accessibility of the drug to the epithelial membrane. The powder SCT/NAC/ethylcellulose formulation did not induce irritation or histological damage to the nasal membrane in rabbits. These results suggest that this formulation technology may be widely applicable for the nasal delivery of peptide or protein drugs. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:183 / 188
页数:6
相关论文
共 31 条
[11]   Intranasal drug delivery [J].
Hussain, AA .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 29 (1-2) :39-49
[12]   Insoluble powder formulation as an effective nasal drug delivery system [J].
Ishikawa, F ;
Murano, M ;
Hiraishi, M ;
Yamaguchi, T ;
Tamai, I ;
Tsuji, A .
PHARMACEUTICAL RESEARCH, 2002, 19 (08) :1097-1104
[13]   Improved nasal bioavailability of elcatonin by insoluble powder formulation [J].
Ishikawa, F ;
Katsura, M ;
Tamai, I ;
Tsuji, A .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 224 (1-2) :105-114
[14]  
Kompella UB, 1991, CRIT REV THER DRUG, V46, P211
[15]   Nasal delivery systems and their effect on deposition and absorption [J].
Kublik, H ;
Vidgren, MT .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 29 (1-2) :157-177
[16]  
LEE VHL, 1988, CRIT REV THER DRUG, V5, P69
[17]  
LEE VHL, 1991, CRIT REV THER DRUG, V8, P91
[18]   Impact of regional intestinal pH modulation on absorption of peptide drugs: Oral absorption studies of salmon calcitonin in beagle dogs [J].
Lee, YH ;
Perry, BA ;
Labruno, S ;
Lee, HS ;
Stern, W ;
Falzone, LM ;
Sinko, PJ .
PHARMACEUTICAL RESEARCH, 1999, 16 (08) :1233-1239
[19]   Enhancement of nasal absorption of large molecular weight compounds by combination of mucolytic agent and nonionic surfactant [J].
Matsuyama, T ;
Morita, T ;
Horikiri, Y ;
Yamahara, H ;
Yoshino, H .
JOURNAL OF CONTROLLED RELEASE, 2006, 110 (02) :347-352
[20]  
MELVILLE GN, 1980, RESPIRATION, V40, P329